Navigation Links
Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex

wo-pronged phase 2/3 clinical approach for Ceflatonin, targeting Gleevec-resistant CML patients who harbour the T315I mutation, as well as CML patients who have failed two tyrosine kinase inhibitors (usually Gleevec and Sprycel).

Gleevec(R)/Glivec(R) is a registered trademark of Novartis AG.

Sprycel(R) is a registered trademark of the Bristol-Myers Squibb Company.

Ceflatonin(R) is a registered trademark of ChemGenex Pharmaceuticals Limited.

About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex's lead compound, Ceflatonin(R), is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) and Quinamed(R) is in phase 2 clinical development for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes, obesity and depression programs, several of which have been partnered with international pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP".

Safe Harbor Statement

Certain statements made herein that use the words "estimate", "project", "intend", "expect", "believe", and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncert
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
Post Your Comments:
(Date:5/29/2015)... , May 29, 2015 Educating ... of the Association for the Advancement of Wound ... With support from AAWC,s corporate partners, the ... Portal on the AAWC website at ... wound care pathway with links to various CME/CEU ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
(Date:5/28/2015)... 2015 The controversy surrounding the use ... myomectomies (procedures to remove uterine fibroids) continues, as ... investigating Johnson & Johnson,s Ethicon, Inc. unit, which ... According to the report published by The Wall ... FBI is trying to determine what the company ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
(Date:5/29/2015)... NJ (PRWEB) May 30, 2015 ... ever changing local and federal regulations, we provide ... of their patients who are suffering from pain, ... says Srinivas Nalamachu, MD, professor of rehabilitation medicine ... Institute in Overland Park, Kansas. , A new ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the ... specialties, now offers The Smartest Rheumatologist . The ... disorders ranging from Fibromyalgia and Osteoporosis, to Arthritis and ... MDLinx, and Caroline Tredway, editorial head of The Smartest ... have on the physicians who participate. Says Tredway, “With ...
(Date:5/29/2015)... The science of Follicular Unit Extraction ... more efficient methods of FUE hair transplantation have increased the ... the most cutting edge hair transplant methods being used to ... of extracting hair from the beard to the scalp. , ... correct male pattern baldness. Beard hair has a life ...
(Date:5/29/2015)... 29, 2015 Jan Wooden Howse lost her ... thing above all else: God does no wrong. , It’s ... her son’s passing is titled “God Does No Wrong.” It ... with great personal tragedy. , “My story has a ... to you into something productive, something healing,” Howse said. , ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 World Patent ... products, announces that it has signed a 10 year ... patent that aims to let people learn about any ... real time. , "This is an exciting day for ... said Scott J. Cooper, CEO and Creative Director of ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
... technologies, testing methods, and processes to improve medical decontamination efforts. ... in other industries, and is using that knowledge to help improve ... ... Midbrook, Inc., a Jackson, MI based manufacturer of medical decontamination ...
... SAN ANTONIO, May 12 Eye Care Centers of ... acquired $65,360,000 of ECCA,s 10-3/4 percent Senior Subordinated Notes ... managed and/or advised by DDJ Capital Management, LLC were ... amount, plus accrued interest to the purchase date. The ...
... a meeting today with President Obama and business leaders, ... drew praise for their innovative employee health care and ... the meeting, President Obama referred to the participants, which ... President and CEO Steven Burd, as "some of the ...
... today,s release of the annual Social Security and ... two largest programs are on a troubled fiscal ... together on reforms of both programs aimed at ... to recognize the underlying structural factors contributing to ...
... Minn. -- Mayo Clinic and Grameen Healthcare are ... leveraging Mayo Clinic,s knowledge and expertise in health ... models. A multi-disciplinary team from Mayo Clinic has ... where it was agreed that following an initial ...
... FARMINGDALE, N.Y., May 12 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has announced their attendance and participation in ... held in Los Angeles, CA, March 19-21, 2009. ...
Cached Medicine News:Health News:Midbrook Developing Decontamination Standards for Medical Industry 2Health News:Midbrook Developing Decontamination Standards for Medical Industry 3Health News:President Obama Praises Retailers as Part of the Health Care Solution 2Health News:Concord Coalition Says New Trustees' Report Demonstrates the Importance of Health Care Cost Control 2Health News:Mayo Clinic and Grameen Healthcare join forces to launch demonstration project 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 3
Enhanced drug and formulary reference with integrated ID treatment guide and tools. Increase patient safety and satisfaction with our premium drug reference....
... STELLARA™ is HIPAA-compliant wireless technology that ... hospital departments and personnel a reality. ... four tages or levels ... patient care, shorter hospital stays and ...
The Duran Flexible Annuloplasty System encompasses both performance and practicality....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: